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Abstract
Whole-exome sequencing of two brothers with drug-resistant, early-onset, focal
epilepsy secondary to extensive type IIA focal cortical dysplasia identified a
paternally inherited, nonsense variant of DEPDC5 (c.C1663T, p.Arg555*). This
variant has previously been reported to cause familial focal epilepsy with vari-
able foci in patients with normal brain imaging. Immunostaining of resected
brain tissue from both brothers demonstrated mammalian target of rapamycin
(mTOR) activation. This report shows the histopathological features of cortical
dysplasia associated with a DEPDC5 mutation, confirms mTOR dysregulation
in the malformed tissue and expands the spectrum of neurological manifesta-
tions of DEPDC5 mutations to include severe phenotypes with large areas of
cortical malformation.
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Introduction
Focal cortical dysplasia (FCD) encompasses a spectrum of
lesions from highly localized bottom of the sulcus dyspla-
sias (BOSD) to extensive multifocal, quadrantic or hemi-
spheric malformations. Although the magnetic resonance
imaging (MRI) appearance can lead to the suspicion of
FCD, definitive diagnosis and classification requires histo-
logical analysis. FCD is characterized by cortical dyslamin-
ation either in isolation (FCD type I) or with dysmorphic
neurons (FCD type IIA) or dysmorphic neurons and bal-
loon cells (FCD type IIB).1 Most cases of FCD are spo-
radic; however, rare familial cases are described.2,3
Deleterious mutations affecting the gene encoding
Dishevelled, Egl-10 and Pleckstrin (DEP) domain-con-
taining protein 5 gene (DEPDC5) cause familial focal epi-
lepsies without obvious cortical malformations with
variable penetrance and expressivity.4–6 DEPDC5 is a
component of the GATOR1 complex, a critical negative
regulator of the mammalian target of rapamycin (mTOR)
pathway.7 Germline heterozygous mutations in DEPDC5
have been associated with lesional epilepsies including
BOSD type FCD.3 Notably, there was considerable intra-
familial variability in the presence or absence of cortical
abnormalities, with only one pedigree showing more than
one individual with FCD. Surgery was not required for
seizure control, therefore the pathological correlates of
these lesions remain unknown. Recently, two studies
showed mutations in DEPDC5 associated with a range of
FCD subtypes and hemimegalencephaly,8,9 yet no
evidence of DEPDC5-mediated mTOR dysregulation has
yet been shown in human brain.
We previously described six families with FCD and
related lesions; one family including two brothers with
neonatal seizures and extensive type IIA FCD.2 To deter-
mine a genetic etiology for FCD in this family, we per-
formed whole-exome sequencing (WES) of both siblings
and identified a heterozygous nonsense mutation in DEP-
DC5.
Patients and Methods
The Royal Children’s Hospital Human Research Ethics
Committee approved the study and informed consent was
obtained from affected individuals or their parents. Clini-
cal details were obtained from parent interview and medi-
cal records. Brain MRI was obtained using age-specific
epilepsy protocols on 1.5 T and 3 T scanners. Resected
tissue was classified by a neuropathologist according to
the system of the ILAE Diagnostic Methods Commission.1
Resected brain tissue was assessed for mTOR activity by
phospho-S6 ribosomal protein antibody staining as
described previously.10 Genomic DNA was isolated from
peripheral blood using standard methods. SNP genotype
data were generated with the Illumina HumanCytoSNP-
12v2 SNP chip and linkage (identity-by-descent [IBD]
sharing) analysis was performed with MERLIN11 (v1.1.2).
Exonic targets were enriched with the TruSeq whole-ex-
ome kit and WES was performed with 100-base pair
paired-end reads on a HiSeq2000 (Illumina, San Diego,
CA). An in-house pipeline was used for data analysis.
Raw sequence data were aligned to the human reference
genome (hg19) with Novoalign (v2.08.01 www.novo-
craft.com). Local re-alignment was performed with Gen-
ome Analysis Toolkit (GATK; v.5-2)12 and variant
detection and annotation utilized GATK’s Unified Geno-
typer (v3.0-0) and ANNOVAR (version dated 2013-05-
20).13 Variants were filtered in step-wise fashion against
criteria including minor allele frequency (MAF) <1%
within the 1000 Genomes Project (release of November
2010) and Exome Variant Server (ESP6500 release; http://
evs.gs.washington.edu/EVS/) data. Variants were then fil-
tered with the following inclusion criteria; (1) within a
linkage region (IBD = 1 or 2), (2) coding/nonsynony-
mous or an insertion or deletion, or in close proximity to
a splice site, (3) a prediction of at least possibly damaging
by either SIFT14 (v5.1.1) or Polyphen-215 (v2.2.2r398)
and (4) presence within a list of 483 candidate genes
potentially associated with brain malformations (Table
S1). Variants of interest were validated in the siblings and
genotyped in extended family members by Sanger
sequencing. The DEPDC5 reference sequences
NM_001242896.1 and NP_001229825.1 were utilized.
Results
Detailed clinical summaries for the two affected siblings
are published as Family 1.2 The extended pedigree is
shown in Figure 1. Both brothers (III:6 and III:7) had
intractable neonatal-onset focal epilepsy, successfully trea-
ted by surgery in infancy; a right hemispherectomy in
III:6 and a right temporo-parietal-occipital resection in
III:7. There was no relevant family history on the mater-
nal side, and mother had a normal brain MRI. The father
(II:3) had four nocturnal tonic clonic seizures and one
daytime seizure beginning at 24 years managed success-
fully with carbamazepine. Right leg jerking was witnessed
at onset on one occasion and post-ictal EEG showed focal
slowing over the left hemisphere. 3 T brain MRI at age
49 years was normal. The paternal uncle (II:2) had noc-
turnal tonic clonic seizures followed by left-sided weak-
ness beginning at 38 years treated successfully with
carbamazepine. 3 T brain MRI at age 53 years showed
mild ventriculomegaly. Results of EEG were not available.
A paternal first cousin (III:2) had a history of febrile sei-
zures. A grand paternal uncle (I:3) had epilepsy with
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onset at age 12 years. A paternal second cousin once
removed (II:5) died during a seizure at 18 years. Further
clinical and imaging details and DNA samples were not
available on these three individuals.
Brain MRI, histopathology and phospho S-6 immuno-
staining are shown in Figure 2A–F. Both brothers had
extensive imaging abnormalities of their right hemisphere
suggestive of FCD. Histopathology showed cortical dysl-
amination and dysmorphic neurons but no balloon cells
consistent with FCDIIA. Phospho S6 labeling was positive
in both.
Analysis of the SNP-chip genotypes for the two siblings
confirmed sibling relatedness and excluded consanguinity.
Linkage analysis identified 69.4% of the siblings’ genomes
was shared (IBD = 1 or 2), in broad agreement with the
expectation for two siblings (25% IBD = 0, 75%
IBD = 1/2). Bioinformatic analysis of WES data identified
a total (union) of 441,161 variants, of which three
(Table 1) fulfilled the inclusion criteria. The nonsense
variant in DEPDC5 (c.C1663T, p.Arg555*) and the mis-
sense variant in the gene encoding DEP domain-contain-
ing mTOR-interacting protein (DEPTOR, c.T338A,
p.Leu113His) were novel while the missense variant in
the gene encoding Neurofibromin 1 (NF1, c.C2159T,
p.Ala720Val, rs148154172) had a reported MAF of 0.5%.
Sanger sequencing confirmed the siblings carried the
DEPDC5, DEPTOR and NF1 variants in the heterozygous
state. Sequencing showed the father, uncle and paternal
grandmother carried the DEPDC5 nonsense variant
(Fig. 1). The father was heterozygous for the DEPTOR
variant, while the mother was heterozygous for the NF1
variant. This DEPDC5 nonsense variant was previously
found in a Dutch family (D1) with familial focal epilepsy
and is not reported in the 1000 genome, ESP6500 or
ExAC databases.4 Family 1 also has Dutch ancestry and
haplotype analysis demonstrated that the DEPDC5 non-
sense mutation arose on a rare haplotype carried by both
our Family 1 and family D1, suggesting shared ancestry.
Discussion
Disruption of the mTOR signaling pathway is increasingly
recognized in the etiology of malformations of cortical
development, with both germline and somatic mutations
in mTOR pathway genes contributing to a range of phe-
notypes.3,16–18 Mutations in DEPDC5, a negative regulator
of mTOR activity, cause focal epilepsy with or without a
cortical malformation visible on MRI.3,4,8,9 Here, we show
a DEPDC5 mutation in two brothers with extensive FCD
type IIA, and a paternal family history of nonlesional
epilepsy.
WES identified three predicted damaging variants
affecting DEPDC5, NF1, and DEPTOR, which encode
components of the mTOR pathway. DEPDC5 encodes a
subunit of the GATOR1 complex which suppresses
mTORC1 activity in response to amino acid deprivation.7
A key step in the activation of mTORC1 is its recruitment
to the lysosomal surface. shRNA-mediated downregula-
tion of DEPDC5 in vitro was associated with constitutive
localization of mTOR to the lysosomal surface and dys-
regulated activity.7 Consistent with these in vitro studies,
we demonstrate for the first time mTOR dysregulation in
brain tissue of individuals with DEPDC5 mutations.
These siblings represent the severe end of the spectrum
of clinical and imaging phenotypes thus far reported in
DEPDC5 mutations. Both brothers had drug-resistant,
early-onset focal epilepsy and imaging showed extensive
FCD, being multifocal hemispheric in one and posterior
quadrantic in the other. The Dutch family reported to
have focal epilepsy and an identical mutation in DEPDC5
all had normal brain MRI.4 It is possible that additional
variants in other genes encoding components of the
mTOR pathway could contribute to the phenotypic vari-
ability associated with DEPDC5, which encompasses both
lesional and nonlesional epilepsies. We demonstrated that
both siblings also carry heterozygous missense alleles
affecting DEPTOR and NF1, the former paternally inher-
ited and the latter maternally inherited. DEPTOR appears
to play a key role in mTOR signaling and directly inhibits
mTOR activity by binding to the FAT domain.19
Similarly, while mutations in NF1 predispose individuals
to neurofibromatosis type I, NF-1 can potentially dysre-
gulate DEPTOR activity via a cascade of interactions that
Figure 1. Pedigree structure and genotyping. Pedigree showing the
epilepsy phenotypes and the genotypes for the variants identified in
DEPDC5, DEPTOR, and NF1.
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includes the suppression of v-maf avian musculoaponeu-
rotic fibrosarcoma oncogene homolog (MAF).20 Neither
brother nor their mother had clinical or imaging features
of neurofibromatosis making the NF1 variant of question-
able significance.
These data expand the understanding of DEPDC5-asso-
ciated epilepsies by showing pathologically proven cortical
dysplasia with associated mTOR activation. It remains
unclear whether the germline mutation in DEPDC5 is suf-
ficient in isolation to cause cortical dysplasia or whether
additional germline or somatic variants of mTOR path-
way genes may also contribute to the severe cortical
dysplasia seen in these siblings. Additional studies of
mTOR pathway genes in germline DNA and DNA from
resected brain tissue from sporadic FCD cases will be
required to explore this hypothesis.
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Figure 2. Brain MRI, histopathology, and phospho-S6 immunostaining. Top row is patient III:6 and bottom row is patient III:7. (A and D) are axial
T2-weighted MRIs at age 6 and 14 weeks, respectively, showing multiple areas of cortical thickening and blurring of the gray white junction
often maximal at the bases of deep abnormal sulci throughout the right hemisphere in patient III:6 and restricted to the right posterior quadrant
in patient III:7 (white arrows). (B and E) are low- and high-power hematoxylin- and eosin-stained images, respectively, of resected cortex showing
cortical dyslamination with clusters of dysmorphic cytomegalic neurons (black arrow) consistent with FCDIIA. (C and F) are images showing
positive phospho S6 immunostaining (Ser235/236, Cell Signaling #2211, rabbit polyclonal, 1:200) in dysmorphic cytomegalic neurons (black
arrows), consistent with mTOR pathway activation. In comparison, (G) shows virtually absent phospho S6 immunostaining in control post mortem
human cortex (scale bar B, 400 lm; F, 80 lm; C, E, and G, 200 lm).
Table 1. Description of candidate variants identified in Family 1.
Chr Position Ref allele Alt allele Gene Transcript Exon Coding change Protein change
Damaging?1
PPH-2/SIFT
8 121,013,800 T A DEPTOR uc011lid.2 3 c.T338A p.L113H prob/prob
17 29,679,412 C T NF1 uc010cso.3 16 c.C2159T p.A720V prob/tol
22 32,211,195 C T DEPDC5 uc011alu.2 21 c.C1663T p.R555X /prob
List of variants that satisfy the primary inclusion criteria of minor allele frequency <0.01, predicted damaging effects to protein function and
presence in the candidate gene list (Table S1). The full criteria are detailed in the methods.
1Predicted pathogenicity by Polyphen-2 (PPH-2) and SIFT with the results “probably damaging” (prob), “tolerated” (tol) and “unscored” ().
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Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Table S1. List of genes causative or potentially associated
with brain malformations derived from extensive litera-
ture searches, including key search terms such as “brain
malformation,” “cortical dysplasia”, and “cortical malfor-
mations.” It includes all currently known genes associated
with brain malformations with potential interacting
partners and associated pathway genes identified by
STRING analysis.
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